An Update on Abpro's HER2/CD3 T cell Engager

Ian Chan, CEO of Abpro, discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering. Abpro's platform can create novel antibodies at industry-leading speeds, which are then reassembled into custom configurations for therapeutic purposes. They have developed bispecific antibodies, particularly T cell engagers for oncology, which are effective against solid tumors. Abpro's lead oncology program for breast cancer, in partnership with Celltrion, is advancing through clinical phases. Additionally, they have an eye care molecule targeting AMD and DME. The recent NASDAQ listing will aid in accelerating R&D and commercialization efforts. Collaborations, like the one with Celltrion, have been instrumental in the company's success.

Can you provide an update on the preclinical development of Abpro's lead HER2/CD3 T cell engager? What are the next key milestones for this program?

The team's been working for a number of years on this, so I think there, this is where our platform was very helpful. We were able to cycle. Through different generations and types of antibodies that we felt would be ultimately the optimal solution for her two was a hard target, so we were able to iterate very quickly early on in the development cycle. So that was step one, and then being able to test them very rapidly was also very important. So as different configurations came out, being able to test them in vitro and also in vivo, to quickly see that there was high safety and also tumor killing. So that happened fairly early on in the life cycle, in certain building blocks had to be created, I would say, on a custom basis, um, in house, for example, proprietary CD3 arm that would allow us to progress through the clinic hopefully much faster. We built that in there were custom building blocks, a lot of iterations that were performed very quickly to get to the final configuration. And then, and then the in vivo work is, I would say, you know, people call it more development type work as we progress toward the clinic. We've done all that as well. And then the factoring, because the molecule was designed to be easily manufacturable, has been straightforward so far so, so that's been the evolution of this molecule.